Capital World Investors’s IO Biotech IOBT Stock Holding History

Capital World Investors’s Portfolio IOBT Stock Details IOBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-418,499	Closed	-$783K	–	514
2023 Q1	$783K	Sell	418,499 -652,812	-61%	-$1.63M	﹤0.01%	506
2022 Q4	$2.46M	Sell	1,071,311 -163,689	-13%	-$433K	﹤0.01%	505
2022 Q3	$3.35M	Hold	1,235,000	–	–	﹤0.01%	507
2022 Q2	$5.77M	Hold	1,235,000	–	–	﹤0.01%	505
2022 Q1	$6.55M	Hold	1,235,000	–	–	﹤0.01%	531
2021 Q4	$8.11M	Buy	+1,235,000	New	+$11.9M	﹤0.01%	560

Other funds holding IOBT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AAM

Aureus Asset Management Boston, Massachusetts $1.65B AUM 26.32% 1-Year Est. Return

Capital World Investors's IOBT Position: Q2 2023 in Review

Capital World Investors sold out of IO Biotech (IOBT) in Q2 2023, closing a stake of 418,499 shares — an estimated $783K sold.

Capital World Investors first reported a position in IOBT in Q4 2021 and held it in 6 quarters. The position peaked at $8.11M in Q4 2021. 15 funds tracked by Wall St. Rank hold IOBT as of Q2 2023.

Capital World Investors reported no remaining IO Biotech position as of Q2 2023 after selling out during the quarter.
Capital World Investors sold 418,499 IO Biotech shares in Q2 2023, an estimated $783K.
Capital World Investors first reported a position in IO Biotech in Q4 2021 and held it in 6 quarters.
Capital World Investors's IO Biotech position peaked at $8.11M in Q4 2021.
15 funds tracked by Wall St. Rank held IO Biotech as of Q2 2023.

Based on Capital World Investors's 13F filing for Q2 2023, filed 11 Aug 2023.